CN109789203B - 与经改造的Fc构建体相关的组合物和方法 - Google Patents

与经改造的Fc构建体相关的组合物和方法 Download PDF

Info

Publication number
CN109789203B
CN109789203B CN201780045710.8A CN201780045710A CN109789203B CN 109789203 B CN109789203 B CN 109789203B CN 201780045710 A CN201780045710 A CN 201780045710A CN 109789203 B CN109789203 B CN 109789203B
Authority
CN
China
Prior art keywords
domain
polypeptide
domain monomer
construct
constructs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780045710.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN109789203A (zh
Inventor
C.J.博斯克斯
J.C.兰辛
D.奥尔蒂斯
L.鲁蒂茨基
N.J.沃什伯恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Momenta Pharmaceuticals Inc
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Priority to CN202210924611.XA priority Critical patent/CN116063540A/zh
Publication of CN109789203A publication Critical patent/CN109789203A/zh
Application granted granted Critical
Publication of CN109789203B publication Critical patent/CN109789203B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Prostheses (AREA)
CN201780045710.8A 2016-05-23 2017-05-23 与经改造的Fc构建体相关的组合物和方法 Active CN109789203B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210924611.XA CN116063540A (zh) 2016-05-23 2017-05-23 与经改造的Fc构建体相关的组合物和方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662340322P 2016-05-23 2016-05-23
US62/340322 2016-05-23
US201762443451P 2017-01-06 2017-01-06
US62/443451 2017-01-06
PCT/US2017/034084 WO2017205434A1 (en) 2016-05-23 2017-05-23 Compositions and methods related to engineered fc constructs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210924611.XA Division CN116063540A (zh) 2016-05-23 2017-05-23 与经改造的Fc构建体相关的组合物和方法

Publications (2)

Publication Number Publication Date
CN109789203A CN109789203A (zh) 2019-05-21
CN109789203B true CN109789203B (zh) 2022-08-05

Family

ID=60412547

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201780045710.8A Active CN109789203B (zh) 2016-05-23 2017-05-23 与经改造的Fc构建体相关的组合物和方法
CN201780045688.7A Pending CN109963869A (zh) 2016-05-23 2017-05-23 与经改造的Fc构建体相关的组合物和方法
CN202210924611.XA Pending CN116063540A (zh) 2016-05-23 2017-05-23 与经改造的Fc构建体相关的组合物和方法
CN202410270902.0A Pending CN118206639A (zh) 2016-05-23 2017-05-23 与经改造的Fc构建体相关的组合物和方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201780045688.7A Pending CN109963869A (zh) 2016-05-23 2017-05-23 与经改造的Fc构建体相关的组合物和方法
CN202210924611.XA Pending CN116063540A (zh) 2016-05-23 2017-05-23 与经改造的Fc构建体相关的组合物和方法
CN202410270902.0A Pending CN118206639A (zh) 2016-05-23 2017-05-23 与经改造的Fc构建体相关的组合物和方法

Country Status (15)

Country Link
US (4) US11623964B2 (enExample)
EP (2) EP3464376A4 (enExample)
JP (5) JP2019519527A (enExample)
KR (3) KR102635635B1 (enExample)
CN (4) CN109789203B (enExample)
AU (2) AU2017272109B2 (enExample)
BR (2) BR112018074032A2 (enExample)
CA (2) CA3025310A1 (enExample)
DK (1) DK3484514T3 (enExample)
ES (1) ES2973251T3 (enExample)
IL (3) IL263211B2 (enExample)
NZ (2) NZ749279A (enExample)
PL (1) PL3484514T3 (enExample)
SG (3) SG10202011624SA (enExample)
WO (2) WO2017205436A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102546875B1 (ko) 2014-05-02 2023-06-26 모멘타 파머슈티컬스 인코포레이티드 공학처리된 ｆｃ 작제물과 관련된 조성물 및 방법
EP3423572B1 (en) 2016-03-02 2023-11-29 Momenta Pharmaceuticals, Inc. Methods related to engineered fc constructs
NZ749279A (en) 2016-05-23 2025-08-29 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
US11220531B2 (en) * 2017-01-06 2022-01-11 Janssen Biotech, Inc. Engineered Fc constructs
WO2020014419A2 (en) * 2018-07-11 2020-01-16 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc-antigen binding domain constructs targeted to pd-l1
BR112021000392A2 (pt) * 2018-07-11 2021-04-06 Momenta Pharmaceuticals, Inc. Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulados
EP3820910A4 (en) * 2018-07-11 2022-06-22 Momenta Pharmaceuticals, Inc. COMPOSITIONS AND METHODS RELATING TO ENGINEERED FC ANTIGEN-BINDING DOMAIN CONSTRUCTS
MX2021000280A (es) * 2018-07-11 2021-11-12 Momenta Pharmaceuticals Inc Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente.
WO2020014413A2 (en) * 2018-07-11 2020-01-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ctla-4
EP3820523A4 (en) * 2018-07-11 2022-03-30 Momenta Pharmaceuticals, Inc. COMPOSITIONS AND METHODS RELATING TO ENGINEERED FC ANTIGEN-BINDING DOMAIN CONSTRUCTS
US20210269546A1 (en) * 2018-07-11 2021-09-02 Momenta Pharmaceuticals, Inc. COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CD38
CA3105985A1 (en) * 2018-07-11 2020-01-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ccr4
KR102661494B1 (ko) 2019-03-08 2024-04-29 에이치엘만도 주식회사 랙구동형 동력 보조 조향장치
WO2021048330A1 (en) 2019-09-13 2021-03-18 CSL Behring Lengnau AG Recombinant igg fc multimers for the treatment of immune complex-mediated kidney disorders
MX2022006703A (es) 2019-12-06 2022-07-12 CSL Behring Lengnau AG Composiciones estables de multimeros fc.
CN111808170A (zh) * 2020-06-29 2020-10-23 江苏为真生物医药技术股份有限公司 多肽、hla-dr蛋白及其制备方法和应用
CN117043190A (zh) * 2020-12-07 2023-11-10 因外泰克斯公司 延长治疗剂在家畜动物中的半衰期的组合物和使用方法
WO2024206820A1 (en) * 2023-03-30 2024-10-03 Dna Twopointo, Inc. Fc engineering for heterodimeric antibody format

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008151088A2 (en) * 2007-06-01 2008-12-11 University Of Maryland, Baltimore Immunoglobulin constant region fc receptor binding agents
US7803769B2 (en) * 2006-10-25 2010-09-28 Amgen Inc. OSK1 peptide analogs and pharmaceutical compositions
WO2014031646A2 (en) * 2012-08-20 2014-02-27 Gliknik Inc. Molecules with antigen binding and polyvalent fc gamma receptor binding activity
WO2014060712A1 (en) * 2012-10-17 2014-04-24 Liverpool School Of Tropical Medicine Immunomodulatory proteins
WO2015054958A1 (zh) * 2013-10-17 2015-04-23 上海张江生物技术有限公司 一类抗CD20-Flex双功能融合蛋白、其制备方法及用途
WO2015095684A1 (en) * 2013-12-20 2015-06-25 Indiana University Research And Technology Corporation Lipidated incretin receptor ligand human immunoglobulin fc-region fusion polypeptides
WO2015168643A2 (en) * 2014-05-02 2015-11-05 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs
US9238080B2 (en) * 2010-05-21 2016-01-19 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2556219B1 (fr) 1983-12-07 1987-06-26 Merieux Inst Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines
US5426641A (en) 1994-01-28 1995-06-20 Bell Communications Research, Inc. Adaptive class AB amplifier for TDMA wireless communications systems
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0975355A2 (en) 1996-06-14 2000-02-02 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
US20090074839A1 (en) 1997-01-22 2009-03-19 Marton Milankovits Pharmaceutical Compositions Primarily for the Treatment and Prevention of Genitourinary Infections and their Extragenital Complications
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
DE60041564D1 (de) 1999-12-24 2009-03-26 Genentech Inc Verfahren und Zusammensetzungen zur Verlängerung der Entsorgungshalbwertszeit von biowirksamen Verbindungen
US20050089932A1 (en) * 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
BRPI0620639A2 (pt) 2006-12-21 2011-11-22 Micromet Ag anticorpos de cadeia simples biespecìficos e composição farmacêutica compreendendo os mesmos
CA2682605A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
KR20100021601A (ko) 2007-05-14 2010-02-25 바이오겐 아이덱 엠에이 인코포레이티드 단일-쇄 Ｆｃ(ＳｃＦｃ) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법
WO2010135521A2 (en) 2009-05-20 2010-11-25 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
PT2247304T (pt) 2008-04-02 2016-08-29 Macrogenics Inc Anticorpos especificos de her2/neu e métodos de utilização dos mesmos
CA2739581A1 (en) 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial eap, emp, and/or adsa proteins
US20100143353A1 (en) 2008-12-04 2010-06-10 Mosser David M POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (lgG) AND METHODS OF USING THE SAME
EP2376105B1 (en) 2008-12-18 2015-07-29 Dana-Farber Cancer Institute, Inc. Nkg2d-fc for immunotherapy
CA2750533A1 (en) 2009-01-23 2010-07-29 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
WO2010135534A2 (en) 2009-05-20 2010-11-25 Children's Medical Center Corporation Compositions for the treatment of metastatic cancer and methods of use thereof
JP5683581B2 (ja) 2009-06-30 2015-03-11 リサーチ ディベロップメント ファウンデーション 免疫グロブリンＦｃポリペプチド
MX2012003396A (es) 2009-09-16 2012-04-10 Genentech Inc Complejos de proteina conteniendo helice super-enrollada y/o enlazador tether y usos de los mismos.
TR201804897T4 (tr) 2009-10-07 2018-06-21 Macrogenics Inc Fukosi̇lasyon ölçüsünün deği̇şi̇mleri̇nden dolayi geli̇şmi̇ş efektör i̇şlevi̇ sergi̇leyen fc bölgesi̇ni̇ i̇çeren poli̇pepti̇tler ve bunlarin kullanimlarina yöneli̇k yöntemler
JP2013511281A (ja) 2009-11-23 2013-04-04 アムジェン インコーポレイテッド 単量体抗体Ｆｃ
GB0922209D0 (en) 2009-12-18 2010-02-03 Univ Nottingham Proteins, nucleic acid molecules and compositions
DK2591006T3 (da) 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Processerbare enkeltkædede molekyler og polypeptider fremstillet ved anvendelse deraf
MX368531B (es) 2010-07-28 2019-10-07 Gliknik Inc Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de fc de inmunoglobulinas multimerizadas ordenadamente.
AU2011288412A1 (en) 2010-08-13 2013-02-21 Medimmune Limited Monomeric polypeptides comprising variant Fc regions and methods of use
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
JP6012624B2 (ja) * 2010-12-23 2016-10-25 ヤンセン バイオテツク，インコーポレーテツド 活性プロテアーゼ耐性抗体Ｆｃ突然変異体
WO2012123949A1 (en) 2011-03-17 2012-09-20 Ramot At Tel-Aviv University Ltd. Bi- and monospecific, asymmetric antibodies and methods of generating the same
US9683052B2 (en) 2011-03-25 2017-06-20 Glenmark Pharmaceuticals S.A. Hetero-dimeric immunoglobulins
WO2013063702A1 (en) * 2011-11-04 2013-05-10 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
AU2013270682A1 (en) * 2012-06-08 2014-12-11 Biogen Ma Inc. Procoagulant compounds
RU2015101699A (ru) 2012-06-21 2016-08-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Слитые полипептиды и конъюгаты полипептида лиганда рецептора инкретина и fc-области с измененной fc-эффекторной функцией
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
EP3835318B1 (en) 2014-01-15 2025-10-29 F. Hoffmann-La Roche AG Fc-region variants with modified fcrn- and maintained protein a-binding properties
EP3094649A1 (en) 2014-01-15 2016-11-23 F. Hoffmann-La Roche AG Fc-region variants with modified fcrn-binding properties
TW201619188A (zh) 2014-03-05 2016-06-01 優稀美生物醫藥公司 多聚體Ｆｃ蛋白質
EP3114137A1 (en) 2014-03-05 2017-01-11 UCB Biopharma SPRL Multimeric fc proteins
BR112016023948A2 (pt) 2014-04-16 2018-01-30 Ucb Biopharma Sprl proteínas fc multiméricas
SG10201913324PA (en) 2014-05-29 2020-03-30 Macrogenics Inc Tri-specific binding molecules and methods of use thereof
EP3423572B1 (en) 2016-03-02 2023-11-29 Momenta Pharmaceuticals, Inc. Methods related to engineered fc constructs
NZ749279A (en) 2016-05-23 2025-08-29 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
US11220531B2 (en) 2017-01-06 2022-01-11 Janssen Biotech, Inc. Engineered Fc constructs

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803769B2 (en) * 2006-10-25 2010-09-28 Amgen Inc. OSK1 peptide analogs and pharmaceutical compositions
WO2008151088A2 (en) * 2007-06-01 2008-12-11 University Of Maryland, Baltimore Immunoglobulin constant region fc receptor binding agents
US9238080B2 (en) * 2010-05-21 2016-01-19 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
WO2014031646A2 (en) * 2012-08-20 2014-02-27 Gliknik Inc. Molecules with antigen binding and polyvalent fc gamma receptor binding activity
WO2014060712A1 (en) * 2012-10-17 2014-04-24 Liverpool School Of Tropical Medicine Immunomodulatory proteins
WO2015054958A1 (zh) * 2013-10-17 2015-04-23 上海张江生物技术有限公司 一类抗CD20-Flex双功能融合蛋白、其制备方法及用途
WO2015095684A1 (en) * 2013-12-20 2015-06-25 Indiana University Research And Technology Corporation Lipidated incretin receptor ligand human immunoglobulin fc-region fusion polypeptides
WO2015168643A2 (en) * 2014-05-02 2015-11-05 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Polymeric human Fc-fusion proteins with modified effector functions;David N. A. Mekhaiel等;《Scientific Reports》;20111019;全文 *

Also Published As

Publication number Publication date
ES2973251T3 (es) 2024-06-19
US12297291B2 (en) 2025-05-13
US11155640B2 (en) 2021-10-26
US20240067757A1 (en) 2024-02-29
PL3484514T3 (pl) 2024-04-29
DK3484514T3 (da) 2024-01-29
JP7045333B6 (ja) 2022-05-06
CN118206639A (zh) 2024-06-18
CA3025306A1 (en) 2017-11-30
IL263213A (en) 2018-12-31
CN116063540A (zh) 2023-05-05
US20220049019A1 (en) 2022-02-17
JP7045333B2 (ja) 2022-03-31
SG10202011624SA (en) 2021-01-28
IL263213B1 (en) 2024-01-01
AU2017272111A1 (en) 2019-01-17
JP2019519527A (ja) 2019-07-11
KR102635635B1 (ko) 2024-02-14
WO2017205436A1 (en) 2017-11-30
WO2017205434A1 (en) 2017-11-30
EP3484514A4 (en) 2020-08-12
SG11201810465RA (en) 2018-12-28
AU2017272111B2 (en) 2024-05-16
AU2017272109A1 (en) 2019-01-17
EP3484514B1 (en) 2023-12-06
CN109963869A (zh) 2019-07-02
JP2022095685A (ja) 2022-06-28
AU2017272109B2 (en) 2024-07-25
JP2022068176A (ja) 2022-05-09
US20210221917A1 (en) 2021-07-22
BR112018074056A2 (pt) 2019-03-06
NZ749279A (en) 2025-08-29
US11623964B2 (en) 2023-04-11
BR112018074032A2 (pt) 2019-02-26
EP3464376A4 (en) 2020-03-18
NZ749292A (en) 2025-08-29
KR20190021255A (ko) 2019-03-05
IL263211B1 (en) 2023-05-01
IL309293A (en) 2024-02-01
KR20220151025A (ko) 2022-11-11
EP3464376A1 (en) 2019-04-10
KR102462084B1 (ko) 2022-11-02
CN109789203A (zh) 2019-05-21
JP2019519528A (ja) 2019-07-11
IL263211A (en) 2018-12-31
KR20190026684A (ko) 2019-03-13
SG11201810466PA (en) 2018-12-28
JP2025026880A (ja) 2025-02-26
IL263213B2 (en) 2024-05-01
CA3025310A1 (en) 2017-11-30
US20190284305A1 (en) 2019-09-19
KR102590061B1 (ko) 2023-10-18
JP7295301B2 (ja) 2023-06-20
IL263211B2 (en) 2023-09-01
EP3484514A1 (en) 2019-05-22

Similar Documents

Publication Publication Date Title
CN109789203B (zh) 与经改造的Fc构建体相关的组合物和方法
US11827682B2 (en) Engineered Fc constructs
CA3049383C (en) Compositions and methods related to engineered fc constructs
WO2020014542A9 (en) Compositions and methods related to engineered fc-antigen binding domain constructs
CN113164592A (zh) 与工程化Fc-抗原结合结构域构建体有关的组合物和方法
RU2816477C2 (ru) КОМПОЗИЦИИ И СПОСОБЫ, СВЯЗАННЫЕ СО СКОНСТРУИРОВАННЫМИ Fc-КОНСТРУКЦИЯМИ
HK40005981A (en) Compositions and methods related to engineered fc constructs
HK40005981B (en) Compositions and methods related to engineered fc constructs

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant